Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Malignancy is increasingly the leading cause of mortality in solid-organ recipients. Cancer incidence among the transplant population is overall threefold to fivefold higher than the general population with poorer outcomes for late-stage disease. Insights into the identification of patients at particular risk of developing a posttransplantation malignancy are imperative to ensure appropriate measures are instigated to reduce associated morbidity and mortality. This review focuses on potential clinical, immunologic, and genetic translational markers aimed at identifying long-term solid-organ transplant patients at high risk of developing cancer.

Original publication

DOI

10.1097/01.TP.0000436907.56425.5c

Type

Journal article

Journal

Transplantation

Publication Date

27/03/2014

Volume

97

Pages

605 - 611

Keywords

Genetic Predisposition to Disease, Humans, Immunosuppressive Agents, Incidence, Neoplasms, Organ Transplantation, Risk Assessment, Time Factors, Treatment Outcome